Fifty 1 Labs, Inc. OTC:FITY announced on July 10, 2026, its strategic evolution into a peptide biotechnology and telehealth company. The company outlined a dual focus on peptide R&D, AI-enabled discovery, and a planned U.S. telehealth platform for peptide-based therapies. CEO Joel J. Gagnier…
VANCOUVER, BC, July 10, 2026, Fifty 1 Labs, Inc. OTC:FITY has announced a major strategic shift, positioning itself as a peptide biotechnology and telehealth company. The firm will concentrate on advancing peptide science, musculoskeletal health, recovery, and evidence-driven product innovation. This move marks a deliberate transformation from its previous business model into a more integrated health-sciences enterprise.
The company’s emerging strategy spans three complementary areas: peptide research and development, AI-enabled discovery workflows, and a planned U.S.-focused telehealth peptide services platform. Fifty 1 Labs intends to pursue a range of peptide products and programs that may include BPC-157, TB-500, MOTS-c, sermorelin, novel analogues, delivery concepts, and related peptide technologies. These candidates reflect a broad exploration of therapeutic possibilities within the peptide space.
Under its R&D umbrella, Fifty 1 Labs plans to conduct a variety of research activities. These are expected to include in silico candidate generation, pathway mapping, formulation assessment, preclinical planning, and clinical-protocol development for future Phase I through Phase III studies, where appropriate. The company is building the infrastructure to move peptide candidates from computational design through early-stage testing and into human trials, assuming regulatory approvals are obtained.
The second pillar involves AI-enabled discovery workflows. While specific details were not provided, the company intends to leverage artificial intelligence to accelerate the identification and optimization of peptide candidates. This approach is designed to complement traditional laboratory methods and improve efficiency in the drug development pipeline.
The third component is a planned telehealth services platform targeted at the U.S. market. Under this model, eligible patients would complete a digital intake process, receive virtual or in-person clinical evaluation, and, where clinically indicated and legally permitted, obtain prescriptions for individualized peptide-based therapies. These therapies would be dispensed by qualified compounding pharmacies. The service line is expected to be structured around licensed clinical oversight, patient-support workflows, laboratory and monitoring pathways, and full compliance with applicable healthcare, telemedicine, pharmacy, compounding, advertising, and professional-practice requirements.
Joel J. Gagnier, Ph.D., MSc, N.D., Chief Executive Officer of Fifty 1 Labs, commented on the announcement. “Fifty 1 Labs is being built around a simple but ambitious premise: peptide innovation should be scientifically credible, clinically responsible, and commercially executable,” he said. “Our strategy is not limited to one product or one channel. We are building a platform that can support discovery, evidence generation, clinical development, partnerships, and direct-to-patient services under an appropriate regulatory posture.”
The company issued a cautionary note regarding its investigative nature. Fifty 1 Labs emphasized that its peptide research candidates remain investigational unless and until applicable regulatory authorization or approval is obtained. The company further stated that there can be no assurance that any peptide candidate, telehealth service, acquisition, partnership, financing, or commercialization initiative will be successfully completed, generate revenue, or achieve profitability.
Fifty 1 Labs, Inc. describes itself as a biotechnology and health-sciences company focused on peptide products, peptide sciences, AI-enabled discovery, musculoskeletal health, sports recovery, and planned U.S. telehealth peptide services. The company’s strategy includes R&D, partnerships, potential acquisitions, clinical-development planning, and commercialization pathways where legally permissible.
Investor inquiries can be directed to [email protected] or by calling 877 505-5006. More information is available at www.fifty1labs.com.
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, identified by words such as “may,” “will,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, involve risks and uncertainties that could cause actual results to differ materially from those projected. Such risks include, but are not limited to, general economic conditions, competition, technological changes, and other factors detailed in the company’s Disclosure Statements. The company undertakes no obligation to update these statements.
SOURCE: Fifty 1 Labs, Inc.
Peptides referenced: BPC-157, TB-500, MOTS-c, Sermorelin.
Vendors referenced: Peptide Sciences, Peptide Technologies, Peptide Biotechnology.
Related reading: Fifty 1 Labs Announces Strategic Evolution into Peptide Biotech and Telehealth, How Researchers Handle BPC-157 in Laboratory Settings, How Researchers Examine BPC-157 in Laboratory Studies, BPC-157 Stability: Key Considerations for Laboratory Researchers.